Company

MacroGenics, Inc.

MacroGenics develops monoclonal antibody-based therapies for cancer.

About

MacroGenics develops monoclonal antibody-based cancer therapeutics, including Lorigerlimab, MGC026, MGC028, and MGD024. Its work focuses on mechanisms intended to improve anti-tumor responses. Founded in 2000 and based in Rockville, US, it raised USD 80 mn in an IPO in October 2013. The company was at the Series D stage.

8Funding rounds

23Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in